CSIMarket
 
Thermogenesis Holdings Inc   (THMO)
Other Ticker:  
 
 
Price: $0.7300 $-0.03 -3.821%
Day's High: $0.7799 Week Perf: -3.18 %
Day's Low: $ 0.71 30 Day Perf: -18.89 %
Volume (M): 12 52 Wk High: $ 4.98
Volume (M$): $ 9 52 Wk Avg: $1.27
Open: $0.75 52 Wk Low: $0.36



 Market Capitalization (Millions $) 2
 Shares Outstanding (Millions) 3
 Employees -
 Revenues (TTM) (Millions $) 8
 Net Income (TTM) (Millions $) -15
 Cash Flow (TTM) (Millions $) 0
 Capital Exp. (TTM) (Millions $) 2

Thermogenesis Holdings Inc
Thermogenesis Holdings Inc is a medical technology company that focuses on developing and commercializing innovative products and therapies in the field of regenerative medicine. The company's main focus is on cell therapy solutions for the treatment of various diseases and conditions, including cancer, wound healing, and orthopedic injuries. Thermogenesis operates through its subsidiary, Asymmetrex, which provides tools and technologies for the isolation and analysis of specific cells for research purposes. The company aims to address unmet medical needs by leveraging advanced cell therapy techniques and technologies.


   Company Address: 2711 Citrus Road Rancho Cordova 95742 CA
   Company Phone Number: 858-5100   Stock Exchange / Ticker: NASDAQ THMO
   THMO is expected to report next financial results on March 29, 2024.


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
• View Complete Report
   



Thermogenesis Holdings Inc

Thermogenesis Holdings Inc. Faces Significant Revenue Decline in Q3 of 2023

Thermogenesis Holdings Inc (THMO) is a company that specializes in the development and commercialization of technologies in the field of regenerative medicine. The company's main focus is on developing cellular and tissue-based products that can be used in various medical procedures.
However, recent financial data for the fiscal period ending on September 30, 2023, indicates that Thermogenesis Holdings Inc has faced some challenges. The company experienced a significant increase in its loss per share, with a reported loss of $-1.44 per share compared to $-0.10 per share in the previous year. This represents a substantial decline in profitability for the company.

Thermogenesis Holdings Inc

Thermogenesis Holdings Inc Faces Fiscal Disaster: Revenue Plunges by 51.502%, Leaving Investors in Despair



In a shocking turn of events, the Laboratory Analytical Instruments company released its financial report for the second quarter of 2023, revealing a significant decline in revenue and widening net deficit. Investors who had high hopes for the company's performance were left disappointed as the numbers painted a bleak picture.
The financial report highlighted a staggering 51.502% decrease in revenue, with sales plummeting to $1.47 million, compared to the corresponding period a year ago. Additionally, the net deficit per share extended to $-0.91, a significant drop from the preceding financial reporting period's net deficit of $-4.07 per share.

Thermogenesis Holdings Inc

Thermogenesis Holdings Inc Faces Significant Revenue Decline, Prompting Need for Financial Turnaround

As a journalist, it is my job to analyze the financial results of Thermogenesis Holdings Inc, which recorded a cumulative net loss of $-15 million during the 12 months ending in the first quarter of 2023. This negative return on investment (ROI) of -179.28% is concerning for the company and its investors.
Looking at the Healthcare sector, it is noted that 751 other companies had a higher ROI, highlighting that Thermogenesis Holdings Inc is not performing as well as its peers. However, there is some optimism in the fact that the overall ranking for ROI has progressed in the Mar 31 2023 quarter, so far to 3605 from the total ROI ranking in the fourth quarter of 2022 at 4799. This shows that the company may be taking some steps to improve its financial performanceThe lower revenue in the financial period ending March 31 2023 is certainly a factor that has led to the losses recorded. Revenue sunk by -3.417% to $2.57 million, with a deficit per share of $-4.07. This is in stark contrast to the $-0.16 per share realized in the financial reporting period a year prior. In comparison to the prior financial reporting period, revenue decreased by -3.886% from $2.68 million and saw an increased deficit from $-0.25 per share.
The net deficit of $-5.182 million for the financial period ending March 31 2023 is larger than the $-2.036 million recorded a year ago. This is troubling for the company, and it must take steps to address the potential reasons for these financial losses, whether it relates to pricing strategies, operational efficiency or something else. The company is expected to report next financial results on May 18, 2023. This will give investors a better understanding of the company?s financial health.
In conclusion, the financial results of Thermogenesis Holdings Inc are concerning overall, and there is no doubt that the company needs to take corrective measures to improve its financial performance. Understanding the reasons behind these losses is essential to rectify the situation, and the company should communicate any steps it plans to take to its investors to restore confidence in its performance.






 

Thermogenesis Holdings Inc's Segments
 
 
• View Complete Report




Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com